Concor 2.5 mg 30 tablets

Tradename

Concor

Concor

Compound:

Bisoprolol fumarate 2.5 mg

Auxiliary components:

microcrystalline cellulose, corn starch, croscarmellose sodium, magnesium stearate, colloidal silicon dioxide.

Properties

Selective beta I-blocker without internal sympathomimetic activity, does not have membrane stabilizing activity. Reduces plasma renin activity, reduces myocardial oxygen demand, reduces heart rate (at rest and during exercise) and cardiac output, while the stroke volume does not significantly decrease. Oppresses AV conduction. It has antianginal and hypotensive effects. In high doses (200 mg or more), it can cause blockade of ß2adrenergic receptors, mainly in the bronchi and vascular smooth muscles.

The antihypertensive effect is associated with a decrease in the minute blood volume, sympathetic stimulation of peripheral vessels, a decrease in the activity of the reninangiotensin system (it is of greater importance for patients with initial renin hypersecretion), restoration of sensitivity in response to a decrease in blood pressure and an effect on the central nervous system.

The antianginal effect is due to a decrease in myocardial oxygen demand as a result of a decrease in heart rate and a decrease in contractility, an increase in diastole, and an improvement in myocardial perfusion.

Indications

Arterial hypertension, prevention of angina attacks, chronic heart failure.

Method of administration and dosage:

The optimal dosage regimen is determined by the doctor. It is necessary to strictly observe the compliance of the used dosage form of particular drug with the indications for use an the dosage regimen.

Contraindications

Acute heart failure, chronic heart failure in the stage of decompensation, cardiogenic shock, collapse, AV block Il and Ill degree (without a pacemaker), SSSU; sinoatrial block, severe bradycardia (heart rate beats / min), Prinzmetal’s angina pectoris, marked decrease in blood pressure (systolic blood pressure mm Hg), severe forms of bronchial asthma and COPD in history, late stages of peripheral circulatory disorders, Raynaud’s disease , pheochromocytoma (without the simultaneous use of alpha-blockers), metabolic acidosis, concomitant use of MAO inhibitors (except for MAO inhibitors of type B), children and adolescents under 18 years of age, hypersensitivity to bisoprolol and other betablockers.

Precautions:

Use with caution in psoriasis and with indications of psoriasis in a family history, diabetes mellitus in the decompensation phase, with a predisposition to allergic

Side effects

From the nervous system: weakness, fatigue, dizziness, headache, sleep disorders, mental disorders (depression, rarely hallucinations), a feeling of cold and paresthesia in the limbs.

On the part of the cardiovascular system:

orthostatic hypotension, bradycardia, impaired AV conduction, the appearance of symptoms of heart failure, aggravation of intermittent claudication and the main clinical symptoms in Raynaud’s syndrome.